Dalbavancin: Difference between revisions
Elcatracho (talk | contribs) |
Elcatracho (talk | contribs) |
||
| Line 31: | Line 31: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
•Gastrointestinal: [[Clostridium difficile | •Gastrointestinal: [[Clostridium difficile]] colitis (<2%), Clostridium difficile diarrhea, [[GI bleed]] (<2% ) | ||
•Hepatic: ALT/SGPT level raised (0.8%) | •Hepatic: ALT/SGPT level raised (0.8%) | ||
•Immunologic: Hypersensitivity reaction | •Immunologic: Hypersensitivity reaction | ||
===Common=== | ===Common=== | ||
Revision as of 06:18, 7 April 2021
Administration
- Type: Antibiotic
- Dosage Forms: 500 mg/vial; reconstituted concentration 20 mg/ml
- Routes of Administration: Intravenous
- Common Trade Names: Dalvance
Adult Dosing
- 1500 mg as single dose or 1000 mg then 500 mg one week later; infuse over 30 minutes
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Special Populations
Pregnancy Rating
- Maternal risk cannot be ruled out
Lactation risk
- Fetal risk cannot be ruled out
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
•Gastrointestinal: Clostridium difficile colitis (<2%), Clostridium difficile diarrhea, GI bleed (<2% ) •Hepatic: ALT/SGPT level raised (0.8%) •Immunologic: Hypersensitivity reaction
Common
•Gastrointestinal: Diarrhea (Up to 4.4%), Nausea (Up to 5.5%) •Neurologic: Headache (Up to 4.7%)
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
